Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2020 Apr;95(4):758-769. doi: 10.1016/j.mayocp.2019.08.006.
Clostridioides difficile infection (CDI) is the leading cause of health care-associated infections in the United States. The increasing incidence and recurrence rates of CDI together with its associated morbidity and mortality are great concerns. Newer treatment methods, such as narrow-spectrum antibiotics, monoclonal antibodies, and microbial replacement therapies, are being developed and implemented. We searched PubMed to identify published literature from 2010 to 2018 using the following keywords: Clostridium difficile, treatment, and therapy. Cited references were also used to identify relevant literature. This review focuses on the current standard of therapy and emerging therapies for CDI and summarizes the updated guidelines on treatment of CDI.
艰难梭菌感染(CDI)是美国医疗保健相关感染的主要原因。CDI 的发病率和复发率不断上升,以及其相关的发病率和死亡率令人担忧。正在开发和实施新的治疗方法,如窄谱抗生素、单克隆抗体和微生物替代疗法。我们在 PubMed 上搜索了 2010 年至 2018 年使用以下关键字发表的文献:艰难梭菌、治疗和疗法。也使用引用的参考文献来确定相关文献。本综述重点介绍 CDI 的当前标准治疗方法和新兴治疗方法,并总结了 CDI 治疗的最新指南。